ANT308 TFA is a vasoactive intestinal polypeptide ( VIP receptor ) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) [1] [2].
In Vivo, ANT308 (100 μg/100 μL PBS, s.c., twice a day for 10 days) TFA reduces the number and size of liver metastases of mice following intraocular or subcutaneous melanoma injection, and shows a trend toward reducing tumor volume at the primary tumor site[2].
In Vitro, ANT308 (0.1-10 μM, 72 h) TFA reduces the viability of B16F10 and HT-144 cells dose-dependently[2]. ANT308 (10 μM, 72 h) TFA decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells[2]. ANT308 (10 μM, 8 h) TFA significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines[2]. ANT308 (72 h) TFA reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling[2].
References:
[1]. Lester C, et al. Chemical Modifications to Enhance the Drug Properties of a VIP Receptor Antagonist (ANT) Peptide. Int J Mol Sci. 2024 Apr 16;25(8):4391.
[2]. Wang W, et al. Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis. Cancer Lett. 2025 Sep 28;628:217855.
In Vivo, ANT308 (100 μg/100 μL PBS, s.c., twice a day for 10 days) TFA reduces the number and size of liver metastases of mice following intraocular or subcutaneous melanoma injection, and shows a trend toward reducing tumor volume at the primary tumor site[2].
In Vitro, ANT308 (0.1-10 μM, 72 h) TFA reduces the viability of B16F10 and HT-144 cells dose-dependently[2]. ANT308 (10 μM, 72 h) TFA decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells[2]. ANT308 (10 μM, 8 h) TFA significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines[2]. ANT308 (72 h) TFA reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling[2].
References:
[1]. Lester C, et al. Chemical Modifications to Enhance the Drug Properties of a VIP Receptor Antagonist (ANT) Peptide. Int J Mol Sci. 2024 Apr 16;25(8):4391.
[2]. Wang W, et al. Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis. Cancer Lett. 2025 Sep 28;628:217855.